[Note: The full text of the article that this abstract summarizes is available for free.]
Disturbances in intestinal microbial ecology and in the immune system of the host have been implicated as a part of the pathogenesis in chronic fatigue syndrome.
Probiotic lactic acid-producing bacteria have been shown to prevent and alleviate gastrointestinal disturbances and to normalize the cytokine profile which might be of an advantage for patients suffering from chronic fatigue syndrome.
The aim of the study was to evaluate the effect of Lactobacillus paracasei ssp. paracasei F19, Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 on fatigue and physical activity in CFS patients.
Fifteen patients fulfilling the criteria set by international researchers in the field at the US Center for Disease Control and Prevention in 1994 for chronic fatigue syndrome, were included in the study.
The patients had high fatigue severity scores and high disability scores.
During the first two weeks baseline observations without treatment were assessed, succeeded by four weeks of intake of a probiotic product and a four-week follow-up period.
The fatigue, health and physical activity was assessed by the use of the Visual Analogue Scales and the SF-12 Health Survey. Fecal samples were collected and the normal microflora was analysed.
Neurocognitive functions improved during the study period while there were no significant changes in fatigue and physical activity scores.
No major changes occurred in the gastrointestinal microflora. At the end of the study 6 of 15 patients reported that they had improved according to the assessment described.
The findings in this study that improvement of health is possible to achieve should encourage further studies with interventions with probiotics in patients with CFS.
Source: Nutrition Journal, Jan 26, 2009;8(1):4. [E-pub ahead of print] PMID: 19171024, by Sullivan A, Nord CE, Evengard GB. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; Division of Infectious Diseases, Department of Clinical Microbiology, Umea University, Umea, Sweden. [E-mail: email@example.com]